Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Liraglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist and the first daily injectable GLP-1 therapy to receive FDA approval. It was the second GLP-1 receptor agonist marketed in the United States (after exenatide) and the first to demonstrate cardiovascular benefit in a major outcomes trial. While now substantially overshadowed in clinical use by semaglutide (the once-weekly successor by the same manufacturer) and tirzepatide, liraglutide remains FDA-approved, holds important historical significance in the development of incretin-based therapy, and retains the longest real-world safety record of any GLP-1 class drug.
Liraglutide is marketed by Novo Nordisk under two brand names:
- Victoza: Type 2 diabetes (with cardiovascular risk reduction in adults with established CVD); once-daily subcutaneous injection (1.8 mg)
- Saxenda: Chronic weight management (adults and adolescents 12+); once-daily subcutaneous injection (3.0 mg)
Both contain the same active molecule at different doses.
Approval timeline:
- 2010: Victoza approved for type 2 diabetes
- December 2014: Saxenda approved for chronic weight management
- 2017: Victoza approved for cardiovascular risk reduction in T2D with established CVD (based on LEADER)
- 2019: Saxenda approved for adolescents 12+ with obesity
- 2024: Victoza approved for pediatric T2D (children 10+)
- 2024: Generic liraglutide became available following patent expiration
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection (Victoza, Saxenda, generic) | ~13 hours |
What it does
Main effects
- Glycemic control in T2D: A1C reductions of 1.0–1.5% across LEAD program trials
- Cardiovascular risk reduction in T2D with established CVD: 13% reduction in major adverse cardiovascular events, 22% reduction in CV death, 15% reduction in all-cause mortality PMID: 27295427
- Modest weight loss for chronic weight management: mean ~8% at 56 weeks with Saxenda 3.0 mg vs ~2.6% placebo PMID: 26132939
- Progression-to-diabetes prevention: 79% reduction in progression from prediabetes to T2D in SCALE Obesity
- Adolescent obesity efficacy: BMI reduction 4.64 percentage points greater than placebo in SCALE Teens PMID: 32233338
- First GLP-1 RA with proven cardiovascular superiority: established the class-effect CV benefit template later confirmed for semaglutide, dulaglutide, tirzepatide
- Longest real-world safety record in the GLP-1 class: 14+ years of FDA-approved clinical use
What to watch for
Common side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation, abdominal pain): dominant tolerability concern; dose-dependent; typically improves with gradual titration
- Pancreatitis: rare but documented; FDA labeling includes warning
- Medullary thyroid carcinoma: boxed warning based on rodent studies; contraindicated in patients with personal or family history of MTC or MEN 2
- Acute kidney injury: typically secondary to dehydration from GI effects
- Cholelithiasis, cholecystitis: modestly increased risk with substantial weight loss
- Hypoglycemia in combination with insulin or sulfonylureas (low risk as monotherapy)
- Heart rate increase (modest, typically 2–3 bpm)
- Injection site reactions: common but typically mild; daily site rotation required
- Less weight loss efficacy than semaglutide (~8% vs ~15%) or tirzepatide (~8% vs ~21%): practical disadvantage when maximum efficacy is the priority
- Daily injection burden: 365 injections/year vs 52 for once-weekly compounds
- Weight regain on discontinuation: typical of the class
Key facts
Key facts worth knowing
- Liraglutide is 97% structurally homologous to native human GLP-1, with a single arginine-for-lysine substitution at position 34 and a C-16 palmitoyl fatty acid side chain at position 26. The fatty acid enables reversible albumin binding, extending the half-life from native GLP-1's ~2 minutes to approximately 13 hours, enabling once-daily dosing.
- The LEADER cardiovascular outcomes trial enrolled 9,340 patients with T2D and high cardiovascular risk, demonstrating a 13% relative risk reduction in major adverse cardiovascular events with median 3.8 years of follow-up. The trial also showed 22% reduction in cardiovascular death and 15% reduction in all-cause mortality, making liraglutide the first GLP-1 receptor agonist with proven cardiovascular superiority. PMID: 27295427
- For weight management, the SCALE Obesity and Prediabetes trial demonstrated mean weight loss of approximately 8% at 56 weeks with liraglutide 3.0 mg (vs −2.6% placebo); 63% of participants achieved ≥5% weight loss and 33% achieved ≥10%. The effect is meaningful but substantially less than the 15% (semaglutide 2.4 mg) or 21% (tirzepatide 15 mg) achievable with newer agents. PMID: 26132939
- Daily injection requirement is a major practical disadvantage versus once-weekly semaglutide and tirzepatide: 365 injections per year vs 52, with higher cumulative burden and more frequent site rotation. This drives substantial preference for newer agents when access permits.
- Generic liraglutide became available in 2024 following patent expiration. The generic provides a cost-effective entry point to GLP-1 therapy and a defensible option where insurance coverage or cost is the dominant constraint.
- Liraglutide is approved for pediatric T2D (10+) and adolescent obesity (12+), a broader pediatric indication than semaglutide or tirzepatide. The 2019 SCALE Teens adolescent approval and 2024 pediatric T2D approval expand options where age-specific access matters. PMID: 32233338
- WADA status: currently NOT prohibited, consistent with other GLP-1 receptor agonists.
Legal status
Legal status
FDA-approved prescription medication. Not a controlled substance. Generic liraglutide available since 2024.